Lipigon Pharmaceuticals ABFRA:9RP EV-to-FCF is 0.25 as of Jul. 11, 2026. The stock has 2 warning signs investors should review. Among 330 Biotechnology companies, Lipigon Pharmaceuticals AB ranks better than 90.3% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Lipigon Pharmaceuticals AB's Enterprise Value is €-0.81 Mil.
Lipigon Pharmaceuticals AB's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €-3.26 Mil. Therefore, Lipigon Pharmaceuticals AB's EV-to-FCF for today is 0.25.
The historical rank and industry rank for Lipigon Pharmaceuticals AB's EV-to-FCF or its related term are showing as below:
FRA:9RP'
s EV-to-FCF Range Over the Past 10 Years
Min: -10.08 Med: -0.79 Max: 0.55
Current: 0.26
During the past 8 years, the highest EV-to-FCF of Lipigon Pharmaceuticals AB was 0.55. The lowest was -10.08. And the median was -0.79.
FRA:9RP's EV-to-FCF is ranked better than 90.3% of 330
companies
in the Biotechnology industry
Industry Median: 16.36
vs FRA:9RP: 0.26
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Lipigon Pharmaceuticals AB (FRA:9RP) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Lipigon Pharmaceuticals AB's PE Ratio (TTM) for today is calculated as:
Lipigon Pharmaceuticals AB's share price for today is €0.0002.
Lipigon Pharmaceuticals AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.009.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Lipigon Pharmaceuticals AB EV-to-FCF Related Terms
Lipigon Pharmaceuticals AB EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Lipigon Pharmaceuticals AB's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lipigon Pharmaceuticals AB EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lipigon Pharmaceuticals AB's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Lipigon Pharmaceuticals AB's EV-to-FCF falls into.
Lipigon Pharmaceuticals AB's current Enterprise Value is €-0.81 Mil.
Lipigon Pharmaceuticals AB's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €-3.26 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lipigon Pharmaceuticals AB (FRA:9RP) has a EV-to-FCF of 0.25 as of Jul. 11, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Lipigon Pharmaceuticals AB and its competitors. According to the industry distribution chart, Lipigon Pharmaceuticals AB ranks #32 out of 330 companies in the Biotechnology industry, placing it in the top 9.7%.
Is Lipigon Pharmaceuticals AB's EV-to-FCF too high?
Lipigon Pharmaceuticals AB's current EV-to-FCF is 0.25. The Biotechnology industry median EV-to-FCF is 16.36. Lipigon Pharmaceuticals AB's value of 0.25 is 98.5% below this industry median. Based on the distribution chart, Lipigon Pharmaceuticals AB ranks #32 out of 330 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers.
How does Lipigon Pharmaceuticals AB's EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Lipigon Pharmaceuticals AB ranks #32 out of 330 companies for EV-to-FCF. This places Lipigon Pharmaceuticals AB in the top 10% of its industry — outperforming the majority of peers. The industry median EV-to-FCF is 16.36. Lipigon Pharmaceuticals AB's value of 0.25 is 98.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 16.36, based on 330 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lipigon Pharmaceuticals AB's current EV-to-FCF of 0.25 is 98.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Lipigon Pharmaceuticals AB and its competitors. For the Biotechnology industry, the median EV-to-FCF is 16.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lipigon Pharmaceuticals AB's current EV-to-FCF is 0.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lipigon Pharmaceuticals AB stock overvalued right now?
Lipigon Pharmaceuticals AB (FRA:9RP) has a current EV-to-FCF of 0.25. The current EV-to-FCF is 0.25 and 98.5% below the Biotechnology industry median of 16.36. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Lipigon Pharmaceuticals AB (FRA:9RP), the current EV-to-FCF is 0.25 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Lipigon Pharmaceuticals AB develops medicines for diseases caused by disorders of the body's handling of fats. It focuses on orphan drugs for unusual diseases where there is no adequate treatment.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:9RP has been successfully added to your 